title: Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089.
abstract: Neuronal acetylcholine nicotinic receptors (nAChRs) are targets for the development of novel treatments of brain diseases. However, adverse effects (for example, emesis or nausea) associated with high drug maximal exposures or C(max) at nAChRs often hinder the advancement of experimental compounds in clinical trials. Therefore, it is essential to explore the feasibility of maintaining exposures below a predetermined C(max) while sustaining targeted CNS effects. By use of a [¹²³I]5-IA [5-[¹²³I]iodo-3-[2(S)-azetidinylmethoxy]pyridine] displacement SPECT imaging paradigm in nonhuman primates, we compared brain nAChR binding activity elicited by either a bolus injection or by slow infusion of an identical dose of a novel neuronal nicotinic agonist, ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride], where the slow infusion scheme was derived from a two-compartment pharmacokinetic modeling designed to limit the C(max). We determined [¹²³I]5-IA displacement using doses of ABT-089 (0.04, 0.4, and 1.0 mg/kg i.v.) that encompassed efficacious drug exposures in nonhuman primates and examined the relationship between ABT-089 displacement ratios and plasma exposures. Our results indicated that calculated displacement ratios were quite similar between the two different dosing regimens despite substantial differences in C(max). In addition, displacement ratios correlated well with drug exposures calculated as the area-under-curve (AUC) of plasma concentration and varied in a dose-dependent manner, suggesting that displacement ratios are driven by the AUC of drug plasma exposure but not C(max). Our data demonstrate the feasibility of predicting plasma exposures using a two-compartment pharmacokinetic model and its potential for optimizing dosing regimens.
authors.affiliation: Advanced Technology, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA. chih-liang.chin@abbott.com
authors.forename: Chih-Liang
authors.initials: CL
authors.lastname: Chin
authors.forename: Robert A
authors.initials: RA
authors.lastname: Carr
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Llano
authors.forename: Olivier
authors.initials: O
authors.lastname: Barret
authors.forename: Hongyu
authors.initials: H
authors.lastname: Xu
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Batis
authors.forename: Andrei O
authors.initials: AO
authors.lastname: Koren
authors.forename: John P
authors.initials: JP
authors.lastname: Seibyl
authors.forename: Kennan C
authors.initials: KC
authors.lastname: Marsh
authors.forename: Gilles
authors.initials: G
authors.lastname: Tamagnan
authors.forename: Michael W
authors.initials: MW
authors.lastname: Decker
authors.forename: Mark
authors.initials: M
authors.lastname: Day
authors.forename: Gerard B
authors.initials: GB
authors.lastname: Fox
mesh_terms: D000818:Animals; D001384:Azetidines / Q000493:pharmacokinetics*; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D008954:Models, Biological; D010215:Papio; D048530:Papio anubis; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D011759:Pyrrolidines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: C426745:5-iodo-3-(2-azetidinylmethoxy)pyridine; D001384:Azetidines; D011725:Pyridines; D011759:Pyrrolidines; C108326:pozanicline